{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:59:27Z","timestamp":1792454367884,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtm.2025.101593","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T16:20:54Z","timestamp":1757521254000},"page":"101593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2958-9767","authenticated-orcid":false,"given":"Takuro","family":"Okai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunsuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sj\u00f6qvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdha","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Galbreath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ho","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saku","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Proetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101593_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.omtm.2025.101593_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101593_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101593_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101593_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib7","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","article-title":"Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results","volume":"30","author":"Sevigny","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101593_bib8","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101593_bib9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/acn3.51165","article-title":"Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations","volume":"7","author":"Hinderer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2025.101593_bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtm.2025.101593_bib11","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ymthe.2021.07.010","article-title":"A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system","volume":"29","author":"Kondratov","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/brainsci11020129","article-title":"Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology","volume":"11","author":"Spronck","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.omtm.2025.101593_bib13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1042\/BST0381484","article-title":"Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis","volume":"38","author":"Wong","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omtm.2025.101593_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib15","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/brain\/awx060","article-title":"Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia","volume":"140","author":"Arrant","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101593_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtm.2025.101593_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101593_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11910-018-0860-4","article-title":"GBA-Associated Parkinson's Disease and Other Synucleinopathies","volume":"18","author":"Gan-Or","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.omtm.2025.101593_bib19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1212\/01.wnl.0000230215.41296.18","article-title":"Glucocerebrosidase mutations are an important risk factor for Lewy body disorders","volume":"67","author":"Goker-Alpan","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2025.101593_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040364","article-title":"GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches","volume":"8","author":"Riboldi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2025.101593_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101593_bib22","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101593_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103425118","article-title":"Wild-type GBA1 increases the alpha-synuclein tetramer-monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice","volume":"118","author":"Glajch","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101593_bib24","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","article-title":"AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy","volume":"25","author":"Morabito","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2025.101593_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094825","article-title":"Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques","volume":"22","author":"Sucunza","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101593_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/hum.2018.072","article-title":"Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy as a Treatment Strategy in Mouse Models of Gaucher Disease","volume":"30","author":"Du","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","article-title":"Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes","volume":"29","author":"Massaro","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101593_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101593_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321145","article-title":"AAV delivery of GBA1 suppresses alpha-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models","volume":"20","author":"Okai","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101593_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ymthe.2004.12.022","article-title":"Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models","volume":"11","author":"Davidoff","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/hum.2022.188","article-title":"Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors","volume":"34","author":"Westhaus","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib33","first-page":"2159","article-title":"Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method","volume":"8","author":"Field","year":"1988","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtm.2025.101593_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/hum.2015.136","article-title":"Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle","volume":"27","author":"Schnepp","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101593_bib36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/hum.2023.060","article-title":"Positron Emission Tomography Quantitative Assessment of Off-Target Whole-Body Biodistribution of I-124-Labeled Adeno-Associated Virus Capsids Administered to Cerebral Spinal Fluid","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105332","article-title":"Adeno-associated virus (AAV)-based gene therapy products: What are toxicity studies in non-human primates showing us?","volume":"138","author":"Baldrick","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.omtm.2025.101593_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2131\/jts.46.57","article-title":"Development challenges associated with rAAV-based gene therapies","volume":"46","author":"Bolt","year":"2021","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.omtm.2025.101593_bib40","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s12035-016-9777-6","article-title":"Transduction Profile of the Marmoset Central Nervous System Using Adeno-Associated Virus Serotype 9 Vectors","volume":"54","author":"Matsuzaki","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.omtm.2025.101593_bib41","series-title":"Physiology, Cerebral Spinal Fluid","author":"Margetis","year":"2025"},{"key":"10.1016\/j.omtm.2025.101593_bib42","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2025.101593_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","article-title":"Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning","volume":"20","author":"Nonnenmacher","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101593_bib44","first-page":"1241","article-title":"Intravenous functional gene transfer throughout the brain of non-human primates using AAV","volume":"18","author":"Chuapoco","year":"2023","journal-title":"Res. Sq."},{"key":"10.1016\/j.omtm.2025.101593_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.medj.2022.11.002","article-title":"Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS","volume":"4","author":"Stanton","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.omtm.2025.101593_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf4888","article-title":"BBB opening with focused ultrasound in nonhuman primates and Parkinson's disease patients: Targeted AAV vector delivery and PET imaging","volume":"9","author":"Blesa","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2025.101593_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145445","article-title":"Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome","volume":"6","author":"Arguello","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101593_bib48","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-023-37632-4","article-title":"Targeting neuronal lysosomal dysfunction caused by beta-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct","volume":"14","author":"Gehrlein","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101593_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100937","article-title":"Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR","volume":"12","author":"Pothin","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtm.2025.101593_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101593_bib51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101593_bib52","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: The phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omtm.2025.101593_bib53","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.slasd.2023.06.002","article-title":"Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells","volume":"28","author":"Naito","year":"2023","journal-title":"SLAS Discov."},{"key":"10.1016\/j.omtm.2025.101593_bib54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/sj.gt.3301948","article-title":"Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina","volume":"10","author":"Kostic","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib55","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/mt.2012.50","article-title":"The beta-globin locus control region in combination with the EF1alpha short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity","volume":"20","author":"Montiel-Equihua","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2025.101593_bib57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/gt.2009.3","article-title":"Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS","volume":"16","author":"Zanta-Boussif","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101593_bib58","unstructured":"Choi, V. and Li, X. (2020). AAV triple-plasmid system. World Patent application WO 2020\/086881A1. 2020 April 30."},{"key":"10.1016\/j.omtm.2025.101593_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74927-8","article-title":"Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101593_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-6588-5_7","article-title":"Cell-Based Measurement of Neutralizing Antibodies Against Adeno-Associated Virus (AAV)","volume":"1521","author":"Jungmann","year":"2017","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:27:16Z","timestamp":1776198436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2329050125001883"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101593","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101593"}}